The DOI matches its Crossref record; the references it cites are not checked yet; 42 of the 126 sources its claims cite were checked for support.
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Open accessAbstract
Only approximately 10% of genetically unselected patients with chemorefractory metastatic colorectal cancer experience tumor regression when treated with the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab ("primary" or "de novo" resistance). Moreover, nearly all patients whose tumors initially respond inevitably become refractory ("secondary" or "acquired" resistance). An ever-increasing number of predictors of both primary and acquired resistance to anti-EGFR antibodies have been described, and it is now evident that most of the underlying mechanisms significantly overlap. By trying to extrapolate a unifying perspective out of many idiosyncratic details, here, we discuss the molecular underpinnings of therapeutic resistance, summarize research efforts aimed to improve patient selection, and present alternative therapeutic strategies that are now under development to increase response and combat relapse.
Overview
CoChat Summary
TL;DR
This review argues that primary and acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC) substantially overlap, with resistant subclones often preexisting and selected under therapy. It summarizes biomarkers and preclinical/clinical strategies proposed to improve patient selection and delay or overcome relapse.
Key findings
- In genetically unselected chemorefractory mCRC, cetuximab or panitumumab monotherapy produces response rates of approximately 10%; KRAS exon 2 mutations occur in approximately 40–45% of CRCs and predict primary resistance, and excluding KRAS exon 2 mutants raises responders to 13–17%, though most KRAS wild-type tumors still do not respond.
- Acquired resistance typically occurs within 3–18 months after treatment initiation; KRAS point mutations and gene copy number gains account for 38–60% of patients who relapse on cetuximab or panitumumab, and ctDNA can identify KRAS alterations 5–10 months before radiographic progression.
- Primary and acquired resistance mechanisms overlap: HER2 amplification was present in 14% of pretreatment tumor cells and increased to 71% posttreatment; MET amplification was found in 3 of 7 patients with acquired resistance and detectable in cell-free DNA as early as 3 months after therapy start; EGFR S492R abrogates cetuximab but not panitumumab binding; no PI3K/AKT pathway alterations had been associated with acquired resistance at the time of review.
- Therapeutic implications include BRAF inhibitor monotherapy response rates of 5% in BRAF-mutant CRC versus 48–67% in BRAF V600E-mutant melanoma; combined EGFR/BRAF inhibition was synergistic preclinically; dual HER2/EGFR targeting induced long-lasting tumor regression in HER2-amplified xenopatients; MET inhibition achieved long-lasting abolition of tumor growth in MET-positive models.
Methods
- Narrative review appraising current knowledge on primary and acquired resistance to anti-EGFR monoclonal antibodies in mCRC, from mechanistic exploration to clinical applications, and summarizing biomarkers and alternative strategies in Table 1.
- Evidence base includes preclinical cell lines, mouse xenografts and GEMMs, patient-derived xenografts/xenopatients, retrospective patient analyses, clinical trials/case reports, and circulating tumor DNA studies; no primary patient cohort or systematic search is described.
Limitations
- Stated in the paper: mutant KRAS is the only validated biomarker in routine practice for selecting mCRC patients for EGFR-targeted therapies; many candidate biomarkers require prospective validation; PTEN expression analysis lacks a consensus method; and EGFR FISH in mCRC still needs interlaboratory standardization.
- Stated in the paper: tumor biopsy may not represent intratumoral and intermetastatic heterogeneity, posttreatment tumor tissue is almost invariably unavailable, and mechanisms of ctDNA release and whether multiple metastases shed ctDNA homogeneously remain unclear.
- Evident from the text: this is a narrative review rather than a systematic review or meta-analysis, with no formal quality assessment or quantitative synthesis; conclusions rely on heterogeneous preclinical and retrospective data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
20 Valid · 1 Not valid · 36 Not checked · 11 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“the best responses of CRC cell xenografts to such combinations were only disease stabilizations or mild tumor regressions [52, 58-60].”
§ Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies > Molecular mechanisms of resistance to anti-EGFR antibodies in patients with metastatic colorectal cancer > BRAF
What the sources say
- Partly supportedcites [52] Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712 sourceExperimental — accuracy not yet measured
The “Combinatorial Targeting of EGFR and BRAF” section reports that cetuximab plus sorafenib reduced viability in CRC cell models. It does not report xenograft experiments or classify their best responses as disease stabilization or mild tumor regression. Page numbers are unavailable in our copy. (LLM, conf=0.85)
- Partly supportedcites [58] Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100–103 sourceExperimental — accuracy not yet measured
The ‘feedback activation of EGFR’ section reports potent growth inhibition in WiDr and VACO432 colorectal cancer xenografts treated with combined cetuximab and PLX4720. It does not characterize the best responses as only disease stabilization or mild tumor regression, so that limitation is not established by our copy. (LLM, conf=0.82)
- Disputedcites [59] Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE et al (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227–235 sourceExperimental — accuracy not yet measured
The Results report that combined vemurafenib and erlotinib caused regressions in most BRAF-mutant CRC xenograft tumors, rather than only stabilization or mild regression. The Discussion describes the xenograft regressions as substantial. Page numbers are not provided in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [60] Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D et al (2012) Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72:779–789 sourceExperimental — accuracy not yet measured
The Vemurafenib/erlotinib section reports increased antitumor activity in HT29 colorectal cancer xenografts, and the Figure 6 caption identifies partial regression. The Vemurafenib/irinotecan/cetuximab section reports greater than 100% tumor-growth inhibition for the vemurafenib–cetuximab doublet. These passages support regression with combined EGFR and BRAF inhibition, but do not establish that the best responses across such combinations were only stabilization or mild regression. (LLM, conf=0.77)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“KRAS point mutations and gene copy number gains are responsible not only for primary but also for acquired resistance in 38–60 % of patients who relapse on cetuximab or panitumumab [37-39].”
§ Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies > Molecular mechanisms of resistance to anti-EGFR antibodies in patients with metastatic colorectal cancer > RAS
What the sources say
- Partly supportedcites [37] Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540 sourceExperimental — accuracy not yet measured
In the paper’s Abstract (page unavailable), nine of 24 patients (38%) whose tumors were initially KRAS wild-type developed detectable KRAS mutations during panitumumab therapy; the authors suggest these mutations mediate acquired resistance. The cited paper does not establish a 60% figure, gene copy-number gains, or the corresponding acquired-resistance rate for cetuximab. (LLM, conf=0.88)
- Supportedcites [38] Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532–536 source
The paper’s Abstract reports secondary KRAS mutations in 6 of 10 patients (60%) who progressed on cetuximab or panitumumab, and KRAS amplification in another patient. It also describes KRAS mutations as a known marker of primary resistance. This source supports the upper end of the cited range; the 38% lower end is not reported in this paper and may come from the other citations attached to the sentence. (LLM, conf=0.87)
- Partly supportedcites [39] Osumi H, Matsusaka S, Shinozaki E, Suenaga M, Mingyon M, Saiura A, Ueno M, Mizunuma N, Yamaguchi T (2013) Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. BMC Res Notes 6:508 sourceExperimental — accuracy not yet measured
The Case presentation (page unavailable) describes a patient whose tumor acquired a KRAS mutation after cetuximab treatment and says it may have conferred resistance. The paper does not report KRAS gene copy-number gains or establish the claimed 38–60% frequency among patients relapsing on cetuximab or panitumumab. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“most KRAS wild-type tumors still do not respond to anti-EGFR moAbs [26, 32].”
§ Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies > Molecular mechanisms of resistance to anti-EGFR antibodies in patients with metastatic colorectal cancer > RAS
What the sources say
- Not checked yetcites [26] Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765 source
- Partly supportedcites [32] Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634 sourceExperimental — accuracy not yet measured
The Response rate section reports that 21 of 124 patients with wild-type KRAS metastatic colorectal cancer had a partial response to panitumumab (17%), supporting the claim that most did not have an objective response. The study tested panitumumab monotherapy in metastatic disease; it does not establish the same rate of nonresponse for all anti-EGFR monoclonal antibodies or all colorectal tumors. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although exclusion of patients with KRAS (exon 2)-mutant tumors has arithmetically increased the percentage of responders up to 13–17 %”
§ Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies > Molecular mechanisms of resistance to anti-EGFR antibodies in patients with metastatic colorectal cancer > RAS
What the sources say
- Not checked yetcites [26] Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765 source
- Partly supportedcites [32] Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634 sourceExperimental — accuracy not yet measured
The Response rate section reports a 17% response rate with panitumumab in patients with wild-type KRAS tumors, versus 0% in those with mutant tumors; it also reports 10% among all KRAS-assessable panitumumab patients. This supports an increased responder percentage after excluding KRAS-mutant tumors, but the paper does not establish the lower figure of 13% or that the 13–17% range applies to anti-EGFR antibodies generally. The reported result is for panitumumab monotherapy in metastatic colorectal cancer. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“as major determinants of primary resistance to cetuximab or panitumumab [17, 27-29].”
§ Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies > Molecular mechanisms of resistance to anti-EGFR antibodies in patients with metastatic colorectal cancer > RAS
What the sources say
- Not checked yetcites [17] Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995 source
- Not checked yetcites [27] Lièvre A, Blons H, Laurent-Puig P (2010) Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29:3033–3043 source
- Partly supportedcites [28] Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96:1166–1169 sourceExperimental — accuracy not yet measured
Our copy supports the cetuximab half: the Materials and Methods (Sequencing analysis) state that 'KRAS exon 2 was PCR-amplified from tumour DNA', and the Abstract and Discussion (p. n/a) report that in 59 chemotherapy-refractory MCRC patients KRAS mutation was 'highly predictive of a non-response to treatment based on cetuximab plus chemotherapy' (associated with PD, P=0.0005; PPV 77.2%, specificity 83.8%; shorter TTP 3 vs 5.5 months). However, panitumumab is nowhere addressed — searches for 'panitumumab' returned only unrelated references and results text — so the extension of the claim to panitumumab is not supported by this source. The paper also frames its own conclusion as needing confirmation ('further studies on larger MCRC series to definitely establish the clinical relevance'), and notes 15 of 43 KRAS wild-type patients still progressed, which softens 'major determinant'. (LLM, conf=0.78)
- Not checked yetcites [29] Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims · 15 with their cited sources checked
Create a free account to see all 68 claims and to verify the 84 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 3
Citations
The citation lists haven’t been fetched yet
References 147 · Cited by 87
Metadata
- Authors
- Leto, S. M., & Trusolino, L.
- Affiliations
- University of Turin (IT)
- Candiolo Cancer Institute (IT)
- Corresponding author
- Trusolino, Livio
- Venue
- Journal of Molecular Medicine
- Published
- 2014-05-10
- Volume
- 92
- Issue
- 7
- Pages
- 709-722
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- PMC
- PMC4055851
- OpenAlex
- W2086061799
- Semantic Scholar
- ce607ce8b17d1df824bf2d305d592d5f78300609
- Cited by
- 87
- References
- 147
- Citations by year
- 2025: 2 · 2024: 7 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 7 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 10 · 2015: 8 · 2014: 3
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (14205)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- anti-EGFR therapy, cetuximab, panitumumab, acquired drug resistance, primary resistance, metastatic colorectal cancer, anti-EGFR monoclonal antibody, predictive biomarkers, patient selection, molecular mechanisms of resistance
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Protein-Tyrosine Kinases, Biomarkers, Tumor, Colorectal Neoplasms, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. https://app.cochat.ai/papers/10.1007/s00109-014-1161-2
- The paper
- Leto, S. M., & Trusolino, L. (2014). Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-014-1161-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.